Craig-Hallum analyst Adam Vogel raised the firm’s price target on Immunome (IMNM) to $36 from $33 and keeps a Buy rating on the shares. The firm notes Immunome reported FY25 results and provided an update that reinforces the transition of the story from binary clinical risk to commercial execution, with a Q2 NDA planned for varegacestat, runway into 2028, and multiple ADC catalysts ahead. With the balance sheet now strengthened, Craig-Hallum views downside as increasingly protected, while upside is tied to differentiation in desmoid and platform validation in 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMNM:
- Immunome price target lowered to $30 from $33 at Stephens
- Immunome price target raised to $39 from $35 at JPMorgan
- Immunome: Buy Rating on Best-in-Class Varegacestat Opportunity and Differentiated Next-Generation ADC Oncology Platform
- Immunome reports FY25 EPS ($2.43), consensus ($2.21)
- Immunome: Advancing Best-in-Class Varegacestat and a Data-Driven ADC Pipeline Support Buy Rating and $40 Target